<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font18 { font-size : 18; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font24">and </span>
   <span class="font18">with </span>
   <span class="font17">for </span>
   <span class="font15">DDIs </span>
   <span class="font15">(.) </span>
   <span class="font15">HCV </span>
   <span class="font14">patients </span>
   <span class="font14">were </span>
   <span class="font13">was </span>
   <span class="font12">outpatient </span>
   <span class="font12">:–. </span>
   <span class="font12">from </span>
   <span class="font12">potential </span>
   <span class="font12">that </span>
   <span class="font12">{background </span>
   <span class="font12">treatment </span>
   <span class="font12">medications </span>
   <span class="font12">The </span>
   <span class="font12">hepatitis </span>
   <span class="font11">DAA </span>
   <span class="font11">most </span>
   <span class="font11">antiviral </span>
   <span class="font11">margin </span>
   <span class="font11">interactions </span>
   <span class="font11">medication </span>
   <span class="font11">{border-style </span>
   <span class="font11">are </span>
   <span class="font11">therapy </span>
   <span class="font11">.%, </span>
   <span class="font11">not </span>
   <span class="font11">px;} </span>
   <span class="font11">regimens </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">chronic </span>
   <span class="font11">significant </span>
   <span class="font11">frequency </span>
   <span class="font11">genotype </span>
   <span class="font11">risk </span>
   <span class="font11">used </span>
   <span class="font11">Engl </span>
   <span class="font11">Med; </span>
   <span class="font11">between </span>
   <span class="font11">DDI </span>
   <span class="font11">[]. </span>
   <span class="font11">al.collab: </span>
   <span class="font11">concomitant </span>
   <span class="font11">drugs </span>
   <span class="font11">fees </span>
   <span class="font11">over </span>
   <span class="font11">all </span>
   <span class="font11">due </span>
   <span class="font11">has </span>
   <span class="font11">infection. </span>
   <span class="font11">liver </span>
   <span class="font11">personal </span>
   <span class="font11">received </span>
   <span class="font11">regular </span>
   <span class="font10">(category </span>
   <span class="font10">DAAs </span>
   <span class="font10">cirrhosis </span>
   <span class="font10">clinical </span>
   <span class="font10">data </span>
   <span class="font10">infection </span>
   <span class="font10">mechanisms </span>
   <span class="font10">this </span>
   <span class="font10">virus </span>
   <span class="font10">years </span>
   <span class="font10">CYP </span>
   <span class="font10">also </span>
   <span class="font10">different </span>
   <span class="font10">each </span>
   <span class="font10">first </span>
   <span class="font10">interaction </span>
   <span class="font10">more </span>
   <span class="font10">patient </span>
   <span class="font10">treated </span>
   <span class="font10">(–) </span>
   <span class="font10">However, </span>
   <span class="font10">Table </span>
   <span class="font10">have </span>
   <span class="font10">modern </span>
   <span class="font10">relevant </span>
   <span class="font10">showed </span>
   <span class="font10">significantly </span>
   <span class="font10">work </span>
   <span class="font10">advanced </span>
   <span class="font10">drug–drug </span>
   <span class="font10">higher </span>
   <span class="font10">lower </span>
   <span class="font10">px; </span>
   <span class="font10">time </span>
   <span class="font10">which </span>
   <span class="font10">{font-family </span>
   <span class="font10">(.%) </span>
   <span class="font10">(A: </span>
   <span class="font10">(Figure </span>
   <span class="font10">.%; </span>
   <span class="font10">All </span>
   <span class="font10">Gilead, </span>
   <span class="font10">Overall, </span>
   <span class="font10">P = ., </span>
   <span class="font10">analysis </span>
   <span class="font10">but </span>
   <span class="font10">font-size </span>
   <span class="font10">frequently </span>
   <span class="font10">other </span>
   <span class="font10">our </span>
   <span class="font10">period </span>
   <span class="font10">real-world </span>
   <span class="font10">regimens, </span>
   <span class="font10">ribavirin </span>
   <span class="font10">sofosbuvir </span>
   <span class="font10">their </span>
   <span class="font10">these </span>
   <span class="font10">using </span>
   <span class="font10">(.%), </span>
   <span class="font10">(Supplementary </span>
   <span class="font10">(ie, </span>
   <span class="font10">AbbVie, </span>
   <span class="font10">A–C </span>
   <span class="font10">Hannover </span>
   <span class="font10">Interactions </span>
   <span class="font10">Medical </span>
   <span class="font10">[–]. </span>
   <span class="font10">age </span>
   <span class="font10">analyzed </span>
   <span class="font10">available </span>
   <span class="font10">been </span>
   <span class="font10">combination </span>
   <span class="font10">disease </span>
   <span class="font10">double; </span>
   <span class="font10">efficacy </span>
   <span class="font10">had </span>
   <span class="font10">increased </span>
   <span class="font10">individual </span>
   <span class="font10">mainly </span>
   <span class="font10">new </span>
   <span class="font10">periods </span>
   <span class="font10">proportion </span>
   <span class="font10">regimens. </span>
   <span class="font10">some </span>
   <span class="font10">still </span>
   <span class="font10">those </span>
   <span class="font10">(.%; </span>
   <span class="font10">(MSD), </span>
   <span class="font10">(n = ), </span>
   <span class="font10">A–B </span>
   <span class="font10">B–C </span>
   <span class="font10">DDIs, </span>
   <span class="font10">DDIs. </span>
   <span class="font10">Drug–Drug </span>
   <span class="font10">Figure </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Infect </span>
   <span class="font10">InvestigatorsLedipasvir </span>
   <span class="font10">Merck </span>
   <span class="font10">No. </span>
   <span class="font10">Potential </span>
   <span class="font10">Squibb, </span>
   <span class="font10">Supplementary </span>
   <span class="font10">This </span>
   <span class="font10">VOX: </span>
   <span class="font10">approved </span>
   <span class="font10">assessed </span>
   <span class="font10">authors </span>
   <span class="font10">became </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">case </span>
   <span class="font10">changed </span>
   <span class="font10">changes </span>
   <span class="font10">cirrhosis. </span>
   <span class="font10">cohort </span>
   <span class="font10">compared </span>
   <span class="font10">direct-acting </span>
   <span class="font10">drug-drug </span>
   <span class="font10">important </span>
   <span class="font10">kidney </span>
   <span class="font10">last </span>
   <span class="font10">less </span>
   <span class="font10">like </span>
   <span class="font10">may </span>
   <span class="font10">mean </span>
   <span class="font10">medications, </span>
   <span class="font10">older </span>
   <span class="font10">patients. </span>
   <span class="font10">polypharmacy </span>
   <span class="font10">previously </span>
   <span class="font10">regimen </span>
   <span class="font10">relevance </span>
   <span class="font10">safety </span>
   <span class="font10">solid; </span>
   <span class="font10">support </span>
   <span class="font10">via </span>
   <span class="font10">well </span>
   <span class="font10">when </span>
   <span class="font10">www.hep-druginteractions.org </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(%) </span>
   <span class="font10">(HCV) </span>
   <span class="font10">.%), </span>
   <span class="font10">Among </span>
   <span class="font10">Bristol </span>
   <span class="font10">Cohort </span>
   <span class="font10">Forum </span>
   <span class="font10">Gastroenterology; </span>
   <span class="font10">GordonSC, </span>
   <span class="font10">Hepatol; </span>
   <span class="font10">IFN-free </span>
   <span class="font10">January </span>
   <span class="font10">July </span>
   <span class="font10">Liver </span>
   <span class="font10">Merck, </span>
   <span class="font10">Myers </span>
   <span class="font10">P-gp </span>
   <span class="font10">P = .) </span>
   <span class="font10">Study </span>
   <span class="font10">[.% </span>
   <span class="font10">about </span>
   <span class="font10">antivirals </span>
   <span class="font10">approval </span>
   <span class="font10">based </span>
   <span class="font10">baseline. </span>
   <span class="font10">bold </span>
   <span class="font10">changing </span>
   <span class="font10">characteristics </span>
   <span class="font10">considered </span>
   <span class="font10">contraindicated </span>
   <span class="font10">contraindications </span>
   <span class="font10">courier; </span>
   <span class="font10">drug </span>
   <span class="font10">drugs, </span>
   <span class="font10">during </span>
   <span class="font10">elderly </span>
   <span class="font10">em; </span>
   <span class="font10">epidemiology </span>
   <span class="font10">era </span>
   <span class="font10">fixed-dose </span>
   <span class="font10">highly </span>
   <span class="font10">inhibitor </span>
   <span class="font10">involved </span>
   <span class="font10">medication. </span>
   <span class="font10">might </span>
   <span class="font10">options </span>
   <span class="font10">pathways </span>
   <span class="font10">patients, </span>
   <span class="font10">pegylated </span>
   <span class="font10">population </span>
   <span class="font10">provided </span>
   <span class="font10">pt;} </span>
   <span class="font10">receiving </span>
   <span class="font10">respectively. </span>
   <span class="font10">several </span>
   <span class="font10">should </span>
   <span class="font10">therapy, </span>
   <span class="font10">therefore </span>
   <span class="font10">transplant </span>
   <span class="font10">various </span>
   <span class="font10">velpatasvir </span>
   <span class="font10">weak </span>
   <span class="font10">widely </span>
   <span class="font10">will </span>
   <span class="font10">without </span>
   <span class="font10">years. </span>
   <span class="font10">years: </span>
  </p>
 </body>
</html>
